+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Anal Cancer Pipeline Analysis and Outlook, 2019

  • ID: 4772489
  • Report
  • May 2019
  • Region: Global
  • 124 pages
  • VPA Research
until Oct 31st 2021


  • Advaxis
  • Biomimetix JV LLC
  • CytomX Therapeutics Inc
  • IMV Inc Incyte Corp
  • MedImmune LLC
  • Ono Pharmaceutical Co Ltd
  • MORE
Anal Cancer pipeline

Anal Cancer pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Anal Cancer R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Anal Cancer report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Anal Cancer as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Anal Cancer with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Anal Cancer pipeline Profiled in detail

Key players actively participating in Anal Cancer pipeline are profiled along with their R&D progress in Anal Cancer treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Anal Cancer pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Anal Cancer treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Anal Cancer pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Anal Cancer pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Anal Cancer pipeline study
  • All recent news and developments related to Anal Cancer drugs are provided
Note: Product cover images may vary from those shown


  • Advaxis
  • Biomimetix JV LLC
  • CytomX Therapeutics Inc
  • IMV Inc Incyte Corp
  • MedImmune LLC
  • Ono Pharmaceutical Co Ltd
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Anal Cancer Disease Overview

3. Anal Cancer Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Anal Cancer Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Anal Cancer Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Anal Cancer companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Anal Cancer Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Advaxis
  • Antiva Biosciences Inc
  • Bayer AG
  • BeiGene Ltd
  • Biomimetix JV LLC
  • Bristol-Myers Squibb Co
  • Cleveland BioLabs Inc
  • Cue Biopharma Inc
  • CytomX Therapeutics Inc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • IMV Inc Incyte Corp
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals BV
  • Kite Pharma Inc
  • MedImmune LLC
  • Merck KGaA
  • Merck Sharp & Dohme Corp
  • Onconova Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • PDS Biotechnology Corp
  • Privo Technologies LLC
  • Sierra Oncology Inc
  • THEVAX Genetics Vaccine USA Inc
  • Turnstone Biologics Inc
  • Virion Therapeutics LLC
Note: Product cover images may vary from those shown